Revenues (Tables)

9 Months Ended

Sep. 30, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue by product and by geographic area

Revenues were as follows (in millions):

	Three months ended September 30,
	2018						2017
	US		ROW		Total		US		ROW		Total
Enbrel®	$	1,242	$	50	$	1,292	$	1,309	$	54	$	1,363
Neulasta®	897		154		1,051		977		146		1,123
Prolia®	354		178		532		298		166		464
Aranesp®	248		229		477		285		231		516
XGEVA®	323		110		433		282		105		387
Sensipar® / Mimpara®	330		79		409		373		84		457
EPOGEN®	252		—		252		264		—		264
Other products	614		450		1,064		509		370		879
Total product sales(1)	$	4,260	$	1,250	$	5,510	$	4,297	$	1,156	$	5,453
Other revenues					394						320
Total revenues(2)					$	5,904					$	5,773

	Nine months ended September 30,
	2018						2017
	US		ROW		Total		US		ROW		Total
Enbrel®	$	3,544	$	155	$	3,699	$	3,838	$	172	$	4,010
Neulasta®	2,854		452		3,306		2,962		458		3,420
Prolia®	1,070		566		1,636		903		491		1,394
Aranesp®	714		689		1,403		851		711		1,562
XGEVA®	994		336		1,330		872		312		1,184
Sensipar® / Mimpara®	1,069		257		1,326		1,052		253		1,305
EPOGEN®	746		—		746		826		—		826
Other products	1,783		1,303		3,086		1,474		1,051		2,525
Total product sales(1)	$	12,774	$	3,758	$	16,532	$	12,778	$	3,448	$	16,226
Other revenues					985						821
Total revenues(2)					$	17,517					$	17,047

^____________ 

⁽¹⁾  Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2018 and 2017.

⁽²⁾  Prior-period amounts are not adjusted under the modified-retrospective method of adoption.